Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options
Open accessThe DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor heterogeneity and lack of biomarkers are thought to be some of the most difficult challenges driving therapeutic resistance and relapse. This review will summarize current therapy for TNBC, studies in treatment resistance and relapse, including data from recent single cell sequencing. We will discuss changes in both the transcriptome and epigenome of TNBC, and we will review mechanisms regulating the immune microenvironment. Lastly, we will provide new perspective in patient stratification, and treatment options targeting transcriptome dysregulation and the immune microenvironment of TNBC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Gene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1279 · Cited by 2,344
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32531-9 · Cited by 1,796
A single-cell and spatially resolved atlas of human breast cancers
Wu, S. Z., Al-Eryani, G., Roden, D. L., Junankar, S., Harvey, K., Andersson, A., Thennavan, A., Wang, C., Torpy, J. R., Bartonicek, N., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00911-1 · Cited by 1,775
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112651 · Cited by 1,274
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Kim, C., Gao, R., Sei, E., Brandt, R., Hartman, J., Hatschek, T., Crosetto, N., Foukakis, T., & Navin, N. E. (2018) · Cell · doi:10.1016/j.cell.2018.03.041 · Cited by 1,104
Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers
Chi, P., Allis, C. D., & Wang, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2876 · Cited by 1,099
Jiang, Y.-Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., Xiao, Y., Yu, K.-D., Liu, Y.-R., Yu, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.001 · Cited by 1,062
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,020
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Wagner, J., Rapsomaniki, M. A., Chevrier, S., Anzeneder, T., Langwieder, C., Dykgers, A., Rees, M., Ramaswamy, A., Muenst, S., Soysal, S. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.005 · Cited by 790
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779
Symmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., Walls, A., Bousamra, A., Ramineni, M., Sinn, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1010 · Cited by 711
Genomic Evolution of Breast Cancer Metastasis and Relapse
Yates, L. R., Knappskog, S., Wedge, D., Farmery, J. H. R., Gonzalez, S., Martincorena, I., Alexandrov, L. B., Van Loo, P., Haugland, H. K., Lilleng, P. K., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.005 · Cited by 665
Genetic predisposition to colorectal cancer
de la Chapelle, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1453 · Cited by 661
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Lu, Y., Chan, Y.-T., Tan, H.-Y., Li, S., Wang, N., & Feng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01197-3 · Cited by 499
Karaayvaz, M., Cristea, S., Gillespie, S. M., Patel, A. P., Mylvaganam, R., Luo, C. C., Specht, M. C., Bernstein, B. E., Michor, F., & Ellisen, L. W. (2018) · Nature Communications · doi:10.1038/s41467-018-06052-0 · Cited by 476
Acquired resistance to immunotherapy and future challenges
Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.2 · Cited by 467
High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
Grosselin, K., Durand, A., Marsolier, J., Poitou, A., Marangoni, E., Nemati, F., Dahmani, A., Lameiras, S., Reyal, F., Frenoy, O., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0424-9 · Cited by 466
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 445
Pioneer Transcription Factors Initiating Gene Network Changes
Zaret, K. S. (2020) · Annual Review of Genetics · doi:10.1146/annurev-genet-030220-015007 · Cited by 414
The language of chromatin modification in human cancers
Zhao, S., Allis, C. D., & Wang, G. G. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00357-x · Cited by 402
Kim, I. S., Gao, Y., Welte, T., Wang, H., Liu, J., Janghorban, M., Sheng, K., Niu, Y., Goldstein, A., Zhao, N., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0373-7 · Cited by 327
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Jiang, Z., Lim, S.-O., Yan, M., Hsu, J. L., Yao, J., Wei, Y., Chang, S.-S., Yamaguchi, H., Lee, H.-H., Ke, B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139434 · Cited by 325
Self-citationAngus, L., Smid, M., Wilting, S. M., van Riet, J., Van Hoeck, A., Nguyen, L., Nik-Zainal, S., Steenbruggen, T. G., Tjan-Heijnen, V. C. G., Labots, M., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0507-7 · Cited by 309
Echeverria, G. V., Ge, Z., Seth, S., Zhang, X., Jeter-Jones, S., Zhou, X., Cai, S., Tu, Y., McCoy, A., Peoples, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav0936 · Cited by 306
Davis, R. T., Blake, K., Ma, D., Gabra, M. B. I., Hernandez, G. A., Phung, A. T., Yang, Y., Maurer, D., Lefebvre, A. E. Y. T., Alshetaiwi, H., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0477-0 · Cited by 300
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
Lehmann, B. D., Colaprico, A., Silva, T. C., Chen, J., An, H., Ban, Y., Huang, H., Wang, L., James, J. L., Balko, J. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26502-6 · Cited by 279
Mehta, A. K., Cheney, E. M., Hartl, C. A., Pantelidou, C., Oliwa, M., Castrillon, J. A., Lin, J.-R., Hurst, K. E., de Oliveira Taveira, M., Johnson, N. T., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00148-7 · Cited by 275
DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma
Sheffield, N. C., Pierron, G., Klughammer, J., Datlinger, P., Schönegger, A., Schuster, M., Hadler, J., Surdez, D., Guillemot, D., Lapouble, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4273 · Cited by 249
Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells
Li, S., Liu, M., Do, M. H., Chou, C., Stamatiades, E. G., Nixon, B. G., Shi, W., Zhang, X., Li, P., Gao, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2850-3 · Cited by 240
Intratumoral Heterogeneity: More Than Just Mutations
Hinohara, K., & Polyak, K. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.03.003 · Cited by 225
Qin, Y., Vasilatos, S. N., Chen, L., Wu, H., Cao, Z., Fu, Y., Huang, M., Vlad, A. M., Lu, B., Oesterreich, S., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0451-5 · Cited by 215
Sharma, D., Saxena, N. K., Davidson, N. E., & Vertino, P. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0402 · Cited by 208
Lan, Y., Moustafa, M., Knoll, M., Xu, C., Furkel, J., Lazorchak, A., Yeung, T.-L., Hasheminasab, S.-M., Jenkins, M. H., Meister, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.008 · Cited by 201
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
Bezzi, M., Seitzer, N., Ishikawa, T., Reschke, M., Chen, M., Wang, G., Mitchell, C., Ng, C., Katon, J., Lunardi, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4463 · Cited by 172
Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling
Huang, H., Hu, J., Maryam, A., Huang, Q., Zhang, Y., Ramakrishnan, S., Li, J., Ma, H., Victor, W., Cheuk, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22445-0 · Cited by 165
Connolly, R. M., Li, H., Jankowitz, R. C., Zhang, Z., Rudek, M. A., Jeter, S. C., Slater, S. A., Powers, P., Wolff, A. C., Fetting, J. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1729 · Cited by 162
Immune cell profiling in cancer: molecular approaches to cell-specific identification
Lyons, Y. A., Wu, S. Y., Overwijk, W. W., Baggerly, K., & Sood, A. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0031-0 · Cited by 160
Coussy, F., Botty, R. E., Château‐Joubert, S., Dahmani, A., Montaudon, É., Leboucher, S., Morisset, L., Painsec, P., Sourd, L., Huguet, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2625 · Cited by 159
TGF-β Signaling in Myeloid Cells Is Required for Tumor Metastasis
Pang, Y., Gara, S. K., Achyut, B. R., Li, Z., Yan, H. H., Day, C.-P., Weiss, J. M., Trinchieri, G., Morris, J. C., & Yang, L. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0527 · Cited by 157
Self-citationYang, L., & Lin, P. C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.001 · Cited by 155
Self-citationNongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression
Tavernari, D., Battistello, E., Dheilly, E., Petruzzella, A. S., Mina, M., Sordet‐Dessimoz, J., Peters, S., Krueger, T., Gfeller, D., Riggi, N., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1274 · Cited by 152
Clonal fitness inferred from time-series modelling of single-cell cancer genomes
Salehi, S., Kabeer, F., Ceglia, N., Andronescu, M., Williams, M. J., Campbell, K. R., Masud, T., Wang, B., Biele, J., Brimhall, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03648-3 · Cited by 152
Głodzik, D., Bosch, A., Hartman, J., Aine, M., Vallon‐Christersson, J., Reuterswärd, C., Karlsson, A., Mitra, S., Niméus, E., Holm, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17537-2 · Cited by 149
Epigenetic Switch–Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer
Deblois, G., Tonekaboni, S. A. M., Grillo, G., Martinez, C., Kao, Y. I., Tai, F., Ettayebi, I., Fortier, A.-M., Savage, P., Fedor, A. N., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1493 · Cited by 147
Dravis, C., Chung, C.-Y., Lytle, N. K., Herrera-Valdez, J., Luna, G., Trejo, C. L., Reya, T., & Wahl, G. M. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.001 · Cited by 141
Sharma, A., Merritt, E., Hu, X., Cruz, A., Jiang, C., Sarkodie, H., Zhou, Z. M., Malhotra, J. D., Riedlinger, G., & De, S. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.045 · Cited by 140
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Fang, Y., Wang, L., Wan, C., Sun, Y., der Jeught, K. V., Zhou, Z., Dong, T., So, K. M., Yu, T., Li, Y., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140837 · Cited by 137
Yomtoubian, S., Lee, S. B., Verma, A., Izzo, F., Markowitz, G. J., Choi, H., Cerchietti, L. C. A., Vahdat, L. T., Brown, K. A., Andreopoulou, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.056 · Cited by 119
Triple-Negative Breast Cancer Cells Recruit Neutrophils by Secreting TGF-β and CXCR2 Ligands
SenGupta, S., Hein, L. E., Xu, Y., Zhang, J., Konwerski, J. R., Li, Y., Johnson, C. N., Cai, D., Smith, J. L., & Parent, C. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.659996 · Cited by 106
Tan, A. H. Y., Tu, W., McCuaig, R., Hardy, K., Donovan, T., Tsimbalyuk, S., Forwood, J. K., & Rao, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01351 · Cited by 105
Post, A. E. M., Smid, M., Nagelkerke, A., Martens, J. W. M., Bussink, J., Sweep, F. C. G. J., & Span, P. N. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2551 · Cited by 104
Horn, L. A., Riskin, J., Hempel, H., Fousek, K., Lind, H., Hamilton, D. H., McCampbell, K. K., Maeda, D. Y., Zebala, J. A., Su, Z., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000326 · Cited by 97
Ericsson, P. I. G., Wulfkhule, J. D., Gallagher, R. I., Sun, X., Axelrod, M. L., Sheng, Q., Luo, N., Gómez, H., Sanchez, V. M., Sanders, M. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0607 · Cited by 92
Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis
Wassef, M., Rodilla, V., Teissandier, A., Zeitouni, B., Gruel, N., Sadacca, B., Irondelle, M., Charruel, M., Ducos, B., Michaud, A., et al. (2015) · Genes & Development · doi:10.1101/gad.269522.115 · Cited by 87
Batra, R. N., Lifshitz, A., Vidaković, A. T., Chin, S., Sati-Batra, A., Sammut, S., Provenzano, E., Ali, H. R., Dariush, A. A., Bruna, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25661-w · Cited by 86
Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment
Yang, Y., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640369 · Cited by 74
Singh, S., Lee, N., Pedroza, D. A., Bado, I., Hamor, C., Zhang, L., Aguirre, S., Hu, J., Shen, Y., Xu, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3714 · Cited by 71
Epigenetics: Unravelling the cancer code
Brower, V. (2011) · Nature · doi:10.1038/471s12a · Cited by 66
Roles of tumor suppressors in regulating tumor-associated inflammation
Yang, L., & Karin, M. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.131 · Cited by 64
Self-citationRinaldi, G., Rossi, M., & Fendt, S. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1397 · Cited by 63
Pineda, B., Díaz‐Lagares, Á., Fidalgo, J. A. P., Burgués, O., González‐Barrallo, I., Crujeiras, A. B., Sandoval, J., Esteller, M., Lluch, A. M., & Eroles, P. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0626-0 · Cited by 62
Silwal‐Pandit, L., Nord, S., Gythfeldt, H. V. D. L., Møller, E. K., Fleischer, T., Rødland, E. A., Krohn, M., Borgen, E., Garred, Ø., Olsen, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0160 · Cited by 59
Mathe, A., Wong‐Brown, M. W., Locke, W. J., Stirzaker, C., Braye, S. G., Forbes, J., Clark, S. J., Avery‐Kiejda, K. A., & Scott, R. J. (2016) · Scientific Reports · doi:10.1038/srep33435 · Cited by 57
So, J. Y., Skrypek, N., Yang, H. H., Merchant, A. S., Nelson, G. W., Chen, W.-D. D., Ishii, H., Chen, J. M., Hu, G., Achyut, B. R., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3339 · Cited by 57
Self-citationChen, I. X., Newcomer, K., Pauken, K. E., Juneja, V. R., Naxerova, K., Wu, M. W., Pinter, M., Sen, D. R., Singer, M., Sharpe, A. H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002806117 · Cited by 55
LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells
Cebrià‐Costa, J. P., Pascual‐Reguant, L., González-Pérez, A., Serra‐Bardenys, G., Querol, J., Cosín, M., Verde, G., Cigliano, R. A., Sanseverino, W., Segura‐Bayona, S., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0969-1 · Cited by 52
Puppe, J., Opdam, M., Schouten, P. C., Jóźwiak, K., Lips, E. H., Severson, T., van de Ven, M., Brambillasca, C. S., Bouwman, P., van Tellingen, O., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4024 · Cited by 51
Genomic Characterization of de novo Metastatic Breast Cancer
Garrido-Castro, A. C., Spurr, L. F., Hughes, M. E., Li, Y. Y., Cherniack, A. D., Kumari, P., Lloyd, M. R., Bychkovsky, B., Barroso‐Sousa, R., Lascio, S. D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1720 · Cited by 45
Chromatin regulators mediate anthracycline sensitivity in breast cancer
Seoane, J. A., Kirkland, J. G., Caswell-Jin, J. L., Crabtree, G. R., & Curtis, C. N. (2019) · Nature Medicine · doi:10.1038/s41591-019-0638-5 · Cited by 44
Huo, X., Li, J., Zhao, F., Ren, D., Ahmad, R., Yuan, X., Du, F., & Zhao, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-07791-y · Cited by 42
Miragaya, J. G., Morán, S., Calleja-Cervantes, M. E., Collado-Solé, A., Paré, L., Gómez, A., Serra, V., Dobrolecki, L. E., Lewis, M. T., Díaz‐Lagares, Á., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0040 · Cited by 39
Bhattacharya, A., Fushimi, A., Yamashita, N., Hagiwara, M., Morimoto, Y., Rajabi, H., Long, M. D., Abdulla, M., Ahmad, R., Street, K., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0672 · Cited by 39
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply.
Schmid, P., Dent, R. A., & O’Shaughnessy, J. (2020) · PubMed · doi:10.1056/nejmc2006684 · Cited by 36
McGrail, D. J., Pilie, P. G., Dai, H., Lam, T., Liang, Y., Voorwerk, L., Kok, M., Zhang, X. H.-F., Rosen, J. M., Heimberger, A. B., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe6201 · Cited by 36
Meyer, B., Clifton, S., Locke, W. J., Luu, P., Du, Q., Lam, D., Armstrong, N. J., Kumar, B., Deng, N., Harvey, K., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01210-6 · Cited by 32
The evolving landscape of immunotherapy in solid tumors
Keilson, J. M., Knochelmann, H. M., Paulos, C. M., Kudchadkar, R. R., & Lowe, M. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26416 · Cited by 31
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Huovinen, R., Jukkola, A., Tanner, M., Ahlgren, J., Auvinen, P., Lahdenperä, O., Villman, K., Nyandoto, P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02054 · Cited by 25
Abdel-Fatah, T. M. A., McArdle, S. E. B., Agarwal, D., Moseley, P. M., Green, A. R., Ball, G. R., Pockley, A. G., Ellis, I. O., Rees, R. C., & Chan, S. Y. T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0610 · Cited by 20
Chromatin Bottlenecks in Cancer
Sarthy, J. F., Henikoff, S., & Ahmad, K. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.01.003 · Cited by 13
Cited by
Yuan, Z., Liu, Z., Zhou, M., Wen, H., & Li, B. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105111 · Cited by 6
Metadata
- Authors
- So, J. Y., Ohm, J., Lipkowitz, S., & Yang, L.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 237
- Pages
- 108253
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W4286508361
- Cited by
- 256
- References
- 112
- FWCI
- 17.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.